A pancreas tumor derived organoid study: from drug screen to precision medicine

Jia Yao; Man Yang; Lawrence Atteh; Pinyan Liu; Yongcui Mao; Wenbo Meng; Xun Li

doi:10.1186/s12935-021-02044-1

A pancreas tumor derived organoid study: from drug screen to precision medicine

Cancer Cell Int. 2021 Jul 27;21(1):398. doi: 10.1186/s12935-021-02044-1.

Authors

Jia Yao^#¹, Man Yang^#², Lawrence Atteh², Pinyan Liu², Yongcui Mao², Wenbo Meng³, Xun Li⁴

Affiliations

¹ Key Laboratory of Biological Therapy and Regenerative Medicine Transformation of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
² The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
³ Department of General Surgery, The First Hospital of Lanzhou University, The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, Gansu, China. mengwb@lzu.edu.cn.
⁴ Department of General Surgery, The First Hospital of Lanzhou University, The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, Gansu, China.

^# Contributed equally.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for treatment guidance is urgently required. This review focuses on pancreatic tumor organoids (PTOs), which can mimic the characteristics of the original tumor in vitro. As a powerful tool with several applications, PTOs represent a new strategy for targeted therapy in pancreatic cancer and contribute to the advancement of the field of personalized medicine.

Keywords: Drug screen; Pancreas cancer; Pancreas tumor derived organoids (PTOs); Pancreatic ductal adenocarcinoma (PDAC); Precision medicine.

Publication types

Review

Abstract

Publication types

Grants and funding